Compare Enveric Biosciences Inc (ENVB) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PepsiCo, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while PepsiCo, Inc. trades at $127.7 (market cap $168.88B). The key difference: PepsiCo, Inc. is far larger — about 25243.6× Enveric Biosciences Inc's market cap, and PepsiCo, Inc. pays a 4.78% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and PepsiCo, Inc. for 107 Days on average.
| ENVB | PEP | |
|---|---|---|
Market Cap | $6.69M | $168.88B |
Volume | 41,141 | 13,263,972 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $170.44 |
52-Week Low | $1.27 | $123.64 |
Typical Hold Time | 14 Days | 107 Days |
Enterprise Value | -$1.60M | $211.38B |
Dividend Yield | — | 4.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PepsiCo (PEP) trades at $128.88, up 2.52% today, with strong earnings momentum as it has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals from moving averages but bullish oscillators, trading near support at $123. Fundamentally, PEP maintains solid profitability with 10.78% net margin and 51.59% ROE, though revenue growth remains modest at 2.2% in 2025. Recent news highlights price adjustments on snack products to address consumer pushback on high prices.
PEP offers value with a 16.22 P/E below industry averages and a 12.7% upside to the $145.25 consensus target, supported by 30% analyst buy ratings. However, risks include competitive pressure, margin compression from pricing actions, and technical weakness. The company's consistent dividend and earnings beats provide stability, but investors should monitor North American sales recovery and inflation impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
